Full Text Journal Articles by
Author Alana L Welm


Find full text journal articles

Enrichment of Collagen Fragments Using Dimeric Collagen Hybridizing Peptide for Urinary Collagenomics.

Julian L Kessler, Yang Li, Jaime Fornetti, Alana L Welm, S Michael Yu,

Collagen remodeling in normal and pathologic conditions releases numerous collagen fragments into biological fluids. Although a few collagen fragments have been tested as biomarkers for disease indication, most occur at trace levels, making them nearly impossible to detect even with modern analytical tools. Here we report a new way to ... Read more >>

J. Proteome Res. (Journal of proteome research)
[2020, :]

Cited: 0 times

View full text PDF listing >>

Epigenetic silencing of TGFBI confers resistance to trastuzumab in human breast cancer.

Sònia Palomeras, Ángel Diaz-Lagares, Gemma Viñas, Fernando Setien, Humberto J Ferreira, Glòria Oliveras, Ana B Crujeiras, Alejandro Hernández, David H Lum, Alana L Welm, Manel Esteller, Teresa Puig,

BACKGROUND:Acquired resistance to trastuzumab is a major clinical problem in the treatment of HER2-positive (HER2+) breast cancer patients. The selection of trastuzumab-resistant patients is a great challenge of precision oncology. The aim of this study was to identify novel epigenetic biomarkers associated to trastuzumab resistance in HER2+ BC patients. METHODS:We ... Read more >>

Breast Cancer Res. (Breast Cancer Research : BCR)
[2019, 21(1):79]

Cited: 0 times

View full text PDF listing >>


The importance of developing therapies targeting the biological spectrum of metastatic disease.

Andries Zijlstra, Ariana Von Lersner, Dihua Yu, Lucia Borrello, Madeleine Oudin, Yibin Kang, Erik Sahai, Barbara Fingleton, Ulrike Stein, Thomas R Cox, John T Price, Yasumasa Kato, Alana L Welm, Julio A Aguirre-Ghiso, ,

Great progress has been made in cancer therapeutics. However, metastasis remains the predominant cause of death from cancer. Importantly, metastasis can manifest many years after initial treatment of the primary cancer. This is because cancer cells can remain dormant before forming symptomatic metastasis. An important question is whether metastasis research ... Read more >>

Clin. Exp. Metastasis (Clinical & experimental metastasis)
[2019, 36(4):305-309]

Cited: 0 times

View full text PDF listing >>

Publisher Correction: Protective autophagy elicited by RAF→MEK→ERK inhibition suggests a treatment strategy for RAS-driven cancers.

Conan G Kinsey, Soledad A Camolotto, Amelie M Boespflug, Katrin P Guillen, Mona Foth, Amanda Truong, Sophia S Schuman, Jill E Shea, Michael T Seipp, Jeffrey T Yap, Lance D Burrell, David H Lum, Jonathan R Whisenant, G Weldon Gilcrease, Courtney C Cavalieri, Kaitrin M Rehbein, Stephanie L Cutler, Kajsa E Affolter, Alana L Welm, Bryan E Welm, Courtney L Scaife, Eric L Snyder, Martin McMahon,

In the version of this article initially published, the label over the bottom schematic in Fig. 1a was "pH > 5.0"; it should have been "pH < 5.0". Further, the original article misspelt the surname of Katrin P. Guillen as "Gullien". These errors have been corrected in the print, PDF ... Read more >>

Nat. Med. (Nature medicine)
[2019, 25(5):861]

Cited: 1 time

View full text PDF listing >>

Protective autophagy elicited by RAF→MEK→ERK inhibition suggests a treatment strategy for RAS-driven cancers.

Conan G Kinsey, Soledad A Camolotto, Amelie M Boespflug, Katrin P Guillen, Mona Foth, Amanda Truong, Sophia S Schuman, Jill E Shea, Michael T Seipp, Jeffrey T Yap, Lance D Burrell, David H Lum, Jonathan R Whisenant, G Weldon Gilcrease, Courtney C Cavalieri, Kaitrin M Rehbein, Stephanie L Cutler, Kajsa E Affolter, Alana L Welm, Bryan E Welm, Courtney L Scaife, Eric L Snyder, Martin McMahon,

Pancreatic ductal adenocarcinoma (PDA) was responsible for ~ 44,000 deaths in the United States in 2018 and is the epitome of a recalcitrant cancer driven by a pharmacologically intractable oncoprotein, KRAS1-4. Downstream of KRAS, the RAF→MEK→ERK signaling pathway plays a central role in pancreatic carcinogenesis5. However, paradoxically, inhibition of this pathway ... Read more >>

Nat. Med. (Nature medicine)
[2019, 25(4):620-627]

Cited: 17 times

View full text PDF listing >>

Understanding the Bone in Cancer Metastasis.

Jaime Fornetti, Alana L Welm, Sheila A Stewart,

The bone is the third most common site of metastasis for a wide range of solid tumors including lung, breast, prostate, colorectal, thyroid, gynecologic, and melanoma, with 70% of metastatic prostate and breast cancer patients harboring bone metastasis.1 Unfortunately, once cancer spreads to the bone, it is rarely cured and ... Read more >>

J. Bone Miner. Res. (Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research)
[2018, 33(12):2099-2113]

Cited: 7 times

View full text PDF listing >>

X-Ray of Excised Cancerous Breast Tissue Does Not Affect Clinical Biomarker Expression.

Isaac E Lloyd, Alana L Welm, Yoko DeRose, Leigh A Neumayer, Jessica L Kohan, Elisabeth M Malmberg, Mohamed E Salama, Rachel E Factor,

CONTEXT:College of American Pathologists (CAP) and the American Society of Clinical Oncology have emphasized the need to reduce preanalytic variables for evaluating predictive biomarker expression in breast cancer. Postoperative x-ray of excised breast tissue is commonplace, yet is a variable that has not been investigated previously. We asked whether such ... Read more >>

Appl. Immunohistochem. Mol. Morphol. (Applied immunohistochemistry & molecular morphology : AIMM)
[2018, 26(7):501-508]

Cited: 0 times

View full text PDF listing >>

Inhibition of RON kinase potentiates anti-CTLA-4 immunotherapy to shrink breast tumors and prevent metastatic outgrowth.

Huseyin Atakan Ekiz, Shu-Chin Alicia Lai, Harika Gundlapalli, Fadi Haroun, Matthew A Williams, Alana L Welm,

The advent of immune checkpoint blockade as a new strategy for immunotherapy has changed the outlook for many aggressive cancers. Although complete tumor eradication is attainable in some cases, durable clinical responses are observed only in a small fraction of patients, underlining urgent need for improvement. We previously showed that ... Read more >>

Oncoimmunology (Oncoimmunology)
[2018, 7(9):e1480286]

Cited: 3 times

View full text PDF listing >>

Cancer Cells Co-opt the Neuronal Redox-Sensing Channel TRPA1 to Promote Oxidative-Stress Tolerance.

Nobuaki Takahashi, Hsing-Yu Chen, Isaac S Harris, Daniel G Stover, Laura M Selfors, Roderick T Bronson, Thomas Deraedt, Karen Cichowski, Alana L Welm, Yasuo Mori, Gordon B Mills, Joan S Brugge,

Cancer cell survival is dependent on oxidative-stress defenses against reactive oxygen species (ROS) that accumulate during tumorigenesis. Here, we show a non-canonical oxidative-stress defense mechanism through TRPA1, a neuronal redox-sensing Ca2+-influx channel. In TRPA1-enriched breast and lung cancer spheroids, TRPA1 is critical for survival of inner cells that exhibit ROS ... Read more >>

Cancer Cell (Cancer cell)
[2018, 33(6):985-1003.e7]

Cited: 9 times

View full text PDF listing >>

NetH2pan: A Computational Tool to Guide MHC Peptide Prediction on Murine Tumors.

Christa I DeVette, Massimo Andreatta, Wilfried Bardet, Steven J Cate, Vanessa I Jurtz, Kenneth W Jackson, Alana L Welm, Morten Nielsen, William H Hildebrand,

With the advancement of personalized cancer immunotherapies, new tools are needed to identify tumor antigens and evaluate T-cell responses in model systems, specifically those that exhibit clinically relevant tumor progression. Key transgenic mouse models of breast cancer are generated and maintained on the FVB genetic background, and one such model ... Read more >>

Cancer Immunol Res (Cancer immunology research)
[2018, 6(6):636-644]

Cited: 1 time

View full text PDF listing >>

RON kinase: A target for treatment of cancer-induced bone destruction and osteoporosis.

Kelsi Andrade, Jaime Fornetti, Ling Zhao, Scott C Miller, R Lor Randall, Neysi Anderson, Susan E Waltz, Mark McHale, Alana L Welm,

Bone destruction occurs in aging and numerous diseases, including osteoporosis and cancer. Many cancer patients have bone osteolysis that is refractory to state-of-the-art treatments, which block osteoclast activity with bisphosphonates or by inhibiting the receptor activator of nuclear factor κB ligand (RANKL) pathway. We previously showed that macrophage-stimulating protein (MSP) ... Read more >>

Sci Transl Med (Science translational medicine)
[2017, 9(374):]

Cited: 9 times

View full text PDF listing >>

A Biobank of Breast Cancer Explants with Preserved Intra-tumor Heterogeneity to Screen Anticancer Compounds.

Alejandra Bruna, Oscar M Rueda, Wendy Greenwood, Ankita Sati Batra, Maurizio Callari, Rajbir Nath Batra, Katherine Pogrebniak, Jose Sandoval, John W Cassidy, Ana Tufegdzic-Vidakovic, Stephen-John Sammut, Linda Jones, Elena Provenzano, Richard Baird, Peter Eirew, James Hadfield, Matthew Eldridge, Anne McLaren-Douglas, Andrew Barthorpe, Howard Lightfoot, Mark J O'Connor, Joe Gray, Javier Cortes, Jose Baselga, Elisabetta Marangoni, Alana L Welm, Samuel Aparicio, Violeta Serra, Mathew J Garnett, Carlos Caldas,

The inter- and intra-tumor heterogeneity of breast cancer needs to be adequately captured in pre-clinical models. We have created a large collection of breast cancer patient-derived tumor xenografts (PDTXs), in which the morphological and molecular characteristics of the originating tumor are preserved through passaging in the mouse. An integrated platform ... Read more >>

Cell (Cell)
[2016, 167(1):260-274.e22]

Cited: 93 times

View full text PDF listing >>

Short-form Ron is a novel determinant of ovarian cancer initiation and progression.

Katherine M Moxley, Luyao Wang, Alana L Welm, Magdalena Bieniasz,

Short-form Ron (sfRon) is an understudied, alternative isoform of the full-length Ron receptor tyrosine kinase. In contrast to Ron, which has been shown to be an important player in many cancers, little is known about the role of sfRon in cancer pathogenesis. Here we report the striking discovery that sfRon ... Read more >>

Genes Cancer (Genes & cancer)
[2016, 7(5-6):169-181]

Cited: 8 times

View full text PDF listing >>

Preclinical Evaluation of Fatty Acid Synthase and EGFR Inhibition in Triple-Negative Breast Cancer.

Ariadna Giró-Perafita, Sònia Palomeras, David H Lum, Adriana Blancafort, Gemma Viñas, Glòria Oliveras, Ferran Pérez-Bueno, Ariadna Sarrats, Alana L Welm, Teresa Puig,

Triple-negative breast cancer (TNBC) lacks an approved targeted therapy. Despite initial good response to chemotherapy, 30% of the patients relapse within 5 years after treatment. EGFR overexpression is a common marker in TNBC, and its expression has been correlated with poor outcome. Inhibition of fatty acid synthase (FASN) activity leads ... Read more >>

Clin. Cancer Res. (Clinical cancer research : an official journal of the American Association for Cancer Research)
[2016, 22(18):4687-4697]

Cited: 10 times

View full text PDF listing >>

RON Signaling Is a Key Mediator of Tumor Progression in Many Human Cancers.

Najme Faham, Alana L Welm,

With an increasing body of literature covering RON receptor tyrosine kinase function in different types of human cancers, it is becoming clear that RON has prominent roles in both cancer cells and in the tumor-associated microenvironment. RON not only activates several oncogenic signaling pathways in cancer cells, leading to more ... Read more >>

Cold Spring Harb. Symp. Quant. Biol. (Cold Spring Harbor symposia on quantitative biology)
[2016, 81:177-188]

Cited: 8 times

View full text PDF listing >>

Preclinical Efficacy of Ron Kinase Inhibitors Alone and in Combination with PI3K Inhibitors for Treatment of sfRon-Expressing Breast Cancer Patient-Derived Xenografts.

Magdalena Bieniasz, Parvathi Radhakrishnan, Najme Faham, Jean-Paul De La O, Alana L Welm,

Recent studies have demonstrated that short-form Ron (sfRon) kinase drives breast tumor progression and metastasis through robust activation of the PI3K pathway. We reasoned that upfront, concurrent inhibition of sfRon and PI3K might enhance the antitumor effects of Ron kinase inhibitor therapy while also preventing potential therapeutic resistance to tyrosine ... Read more >>

Clin. Cancer Res. (Clinical cancer research : an official journal of the American Association for Cancer Research)
[2015, 21(24):5588-5600]

Cited: 12 times

View full text PDF listing >>

Metabolic reprogramming in triple-negative breast cancer through Myc suppression of TXNIP.

Liangliang Shen, John M O'Shea, Mohan R Kaadige, Stéphanie Cunha, Blake R Wilde, Adam L Cohen, Alana L Welm, Donald E Ayer,

Triple-negative breast cancers (TNBCs) are aggressive and lack targeted therapies. Understanding how nutrients are used in TNBCs may provide new targets for therapeutic intervention. We demonstrate that the transcription factor c-Myc drives glucose metabolism in TNBC cells but does so by a previously unappreciated mechanism that involves direct repression of ... Read more >>

Proc. Natl. Acad. Sci. U.S.A. (Proceedings of the National Academy of Sciences of the United States of America)
[2015, 112(17):5425-5430]

Cited: 48 times

View full text PDF listing >>

Molecular dissection of the mechanism by which EWS/FLI expression compromises actin cytoskeletal integrity and cell adhesion in Ewing sarcoma.

Aashi Chaturvedi, Laura M Hoffman, Christopher C Jensen, Yi-Chun Lin, Allie H Grossmann, R Lor Randall, Stephen L Lessnick, Alana L Welm, Mary C Beckerle,

Ewing sarcoma is the second-most-common bone cancer in children. Driven by an oncogenic chromosomal translocation that results in the expression of an aberrant transcription factor, EWS/FLI, the disease is typically aggressive and micrometastatic upon presentation. Silencing of EWS/FLI in patient-derived tumor cells results in the altered expression of hundreds to ... Read more >>

Mol. Biol. Cell (Molecular biology of the cell)
[2014, 25(18):2695-2709]

Cited: 16 times

View full text PDF listing >>

Invasive lobular carcinoma cell lines are characterized by unique estrogen-mediated gene expression patterns and altered tamoxifen response.

Matthew J Sikora, Kristine L Cooper, Amir Bahreini, Soumya Luthra, Guoying Wang, Uma R Chandran, Nancy E Davidson, David J Dabbs, Alana L Welm, Steffi Oesterreich,

Invasive lobular carcinoma (ILC) is a histologic subtype of breast cancer that is frequently associated with favorable outcomes, as approximately 90% of ILC express the estrogen receptor (ER). However, recent retrospective analyses suggest that patients with ILC receiving adjuvant endocrine therapy may not benefit as much as patients with invasive ... Read more >>

Cancer Res. (Cancer research)
[2014, 74(5):1463-1474]

Cited: 41 times

View full text PDF listing >>

The RON receptor tyrosine kinase promotes metastasis by triggering MBD4-dependent DNA methylation reprogramming.

Stéphanie Cunha, Yi-Chun Lin, Elizabeth A Goossen, Christa I DeVette, Mark R Albertella, Stuart Thomson, Mark J Mulvihill, Alana L Welm,

Metastasis is the major cause of death in cancer patients, yet the genetic and epigenetic programs that drive metastasis are poorly understood. Here, we report an epigenetic reprogramming pathway that is required for breast cancer metastasis. Concerted differential DNA methylation is initiated by the activation of the RON receptor tyrosine ... Read more >>

Cell Rep (Cell reports)
[2014, 6(1):141-154]

Cited: 30 times

View full text PDF listing >>

RON promotes the metastatic spread of breast carcinomas by subverting antitumor immune responses.

Henok Eyob, Huseyin Atakan Ekiz, Alana L Welm,

The MSP/RON signaling pathway favors the conversion of micrometastatic lesions to overt metastases by suppressing antitumor immune responses. The loss of RON functions in the host potentiates tumor-specific CD8(+) T-cell responses, hence inhibiting the outgrowth of metastatic cancer cells. Thus, RON inhibitors may potentially prevent the outgrowth of micrometastases in ... Read more >>

Oncoimmunology (Oncoimmunology)
[2013, 2(9):e25670]

Cited: 8 times

View full text PDF listing >>

Inhibition of ron kinase blocks conversion of micrometastases to overt metastases by boosting antitumor immunity.

Henok Eyob, Huseyin Atakan Ekiz, Yoko S Derose, Susan E Waltz, Matthew A Williams, Alana L Welm,

Many "nonmetastatic" cancers have spawned undetectable metastases before diagnosis. Eventual outgrowth of these microscopic lesions causes metastatic relapse and death, yet the events that dictate when and how micrometastases convert to overt metastases are largely unknown. We report that macrophage-stimulating protein and its receptor, Ron, are key mediators in conversion ... Read more >>

Cancer Discov (Cancer discovery)
[2013, 3(7):751-760]

Cited: 26 times

View full text PDF listing >>

Survivin promotion of melanoma metastasis requires upregulation of α5 integrin.

Jodi A McKenzie, Tong Liu, Jae Y Jung, Benjamin B Jones, Huseyin A Ekiz, Alana L Welm, Douglas Grossman,

Survivin is an apoptotic and mitotic regulator that is overexpressed in melanoma and a poor prognostic marker in patients with metastatic disease. We recently showed that Survivin enhances melanoma cell motility through Akt-dependent upregulation of α5 integrin. However, the functional role of Survivin in melanoma metastasis is not clearly understood. ... Read more >>

Carcinogenesis (Carcinogenesis)
[2013, 34(9):2137-2144]

Cited: 18 times

View full text PDF listing >>

Treatment of triple-negative breast cancer using anti-EGFR-directed radioimmunotherapy combined with radiosensitizing chemotherapy and PARP inhibitor.

Fares Al-Ejeh, Wei Shi, Mariska Miranda, Peter T Simpson, Ana Cristina Vargas, Sarah Song, Adrian P Wiegmans, Alex Swarbrick, Alana L Welm, Michael P Brown, Georgia Chenevix-Trench, Sunil R Lakhani, Kum Kum Khanna,

UNLABELLED: Triple-negative breast cancer (TNBC) is associated with poor survival. Chemotherapy is the only standard treatment for TNBC. The prevalence of BRCA1 inactivation in TNBC has rationalized clinical trials of poly(adenosine diphosphate ribose) polymerase (PARP) inhibitors. Similarly, the overexpression of epidermal growth factor receptor (EGFR) rationalized anti-EGFR therapies in this ... Read more >>

J. Nucl. Med. (Journal of nuclear medicine : official publication, Society of Nuclear Medicine)
[2013, 54(6):913-921]

Cited: 32 times

View full text PDF listing >>

Mouse models of breast cancer metastasis to bone.

Kelsi L Kretschmann, Alana L Welm,

Breast cancer frequently metastasizes to bone, where it takes a significant toll on quality of life. Models of bone metastasis are needed in order to better understand the process of bone metastasis and to develop better treatments. Here, we discuss the available mouse models for breast cancer bone metastasis and ... Read more >>

Cancer Metastasis Rev. (Cancer metastasis reviews)
[2012, 31(3-4):579-583]

Cited: 8 times

View full text PDF listing >>


1.0379 s